Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus HUMALOG MIX 50 50 KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus HUMALOG MIX 50 50 KWIKPEN.
ADMELOG SOLOSTAR vs HUMALOG MIX 50/50 KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling.
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
Subcutaneous injection: individualized dose based on metabolic needs, blood glucose monitoring, and prior insulin therapy. Typically administered within 15 minutes before meals or immediately after meals. Total daily dose: 0.5-1.0 units/kg/day in divided doses. For the mix 50/50, half as basal (intermediate-acting component) and half as bolus (rapid-acting component).
None Documented
None Documented
Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals.
0.5-1 hour (insulin lispro); terminal half-life is approximately 1 hour. Clinically, the rapid clearance allows for flexible dosing timing relative to meals.
Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible.
Renal: 60-80% as metabolites; hepatic metabolism accounts for most of the remainder. Fecal excretion is minimal.
Category C
Category C
Insulin
Insulin